Polymorphism and circulating levels of the chemokine CXCL12 in colorectal cancer patients

The chemokine CXCL12, also known as stromal cell-derived factor-1 (SDF-1), is a small protein that regulates leukocyte trafficking and is variably expressed in a number of normal and cancer tissues. CXCL12 as ligand and its receptor CXCR4 have been implicated in colorectal cancer (CRC) progression i...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular medicine 2007-01, Vol.19 (1), p.11-15
Main Authors: Dimberg, Jan, Hugander, Anders, Löfgren, Sture, Wågsäter, Dick
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor - analysis
Case-Control Studies
Chemokine CXCL12
Chemokines, CXC - blood
Chemokines, CXC - genetics
Colorectal Neoplasms - blood
Colorectal Neoplasms - genetics
Colorectal Neoplasms/blood/genetics
Female
Gene Frequency
Humans
INTERDISCIPLINARY RESEARCH AREAS
Male
Medicin och hälsovetenskap
Middle Aged
Older people and ageing
Polymerase Chain Reaction
Polymorphism, Genetic
Polymorphism, Restriction Fragment Length
TVÄRVETENSKAPLIGA FORSKNINGSOMRÅDEN
Äldre och åldrande
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The chemokine CXCL12, also known as stromal cell-derived factor-1 (SDF-1), is a small protein that regulates leukocyte trafficking and is variably expressed in a number of normal and cancer tissues. CXCL12 as ligand and its receptor CXCR4 have been implicated in colorectal cancer (CRC) progression including angiogenesis and metastasis. A CXCL12 gene variant CXCL12-A (CXCL12-G801A, a single nucleotide polymorphism in the 3' untranslated region) is associated with increased susceptibility to breast cancer. Based on the suggested role of CXCL12 in the pathogenesis of cancer we examined the association of the gene variant CXCL12-A with CRC. The polymorphism was analysed with PCR and RFLP methods. Furthermore, the plasma CXCL12 levels from patients with CRC were also examined. There was no significant difference in genotype distribution and allelic frequencies between CRC patients (n=151) and controls (n=141). On the other hand, we found that the carrying rate of allele CXCL12-A was higher in colon cancer patients compared with rectal cancer patients (P=0.017). Analyses by ELISA showed that CRC patients (n=63) had a lower CXCL12 plasma level compared with controls (P
ISSN:1107-3756
1791-244X
1791-244X
DOI:10.3892/ijmm.19.1.11